Concord Medical Services Holdings Limited American Depositary Shares (Each represents thirty (30) Class A ordinary shares) (CCM)

FairStock Score: 20/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I start with business quality and the margin of safety. Concord Medical operates radiotherapy and diagnostic imaging centers in China, with network and hospital segments and technologies such as linear accelerators, proton therapy, gamma knife, and diagnostic imaging. That is a necessary healthcare service, but the supplied numbers show no durable moat or earning power. At the close on 2026-10-13, the price was $3.69 and market cap was $17.4M. FairStock's calculations show a P/E of -1.16, ROE of -21.88%, ROCE of -2.25%, and a debt-to-equity ratio of 1.96. A Piotroski F-Score of 3/9 and Altman Z-Score of -1.14 point to weak financial health and possible distress, not safety. The FairStock Score is 20/100. I am given no revenue or profit growth figures, and the Lynch category is none because only 0 years of filed results exist where 3 are needed. P/B is not available, so I cannot judge asset value. Beta is -0.94, which may indicate low or inverse market correlation, but that does not fix a loss-making, leveraged balance sheet. The 52-week range of $2.79 to $6.80 shows volatility. A negative P/E means there is no meaningful earnings yield to anchor valuation. Without evidence of improving margins, debt reduction, or positive returns, I see a speculative situation rather than a Graham-style bargain. I would need filed results showing durable earnings and a safer balance sheet before considering the price attractive.

In plain English: Concord Medical runs radiotherapy and diagnostic imaging centers in China through network and hospital segments. The supplied numbers suggest a weak business: it is losing money, has negative returns, and carries heavy debt. At the $3.69 close on 2026-10-13, the price does not look cheap against those weak fundamentals.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer